Literature DB >> 16459310

miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting.

Christine Esau1, Scott Davis, Susan F Murray, Xing Xian Yu, Sanjay K Pandey, Michael Pear, Lynnetta Watts, Sheri L Booten, Mark Graham, Robert McKay, Amuthakannan Subramaniam, Stephanie Propp, Bridget A Lollo, Susan Freier, C Frank Bennett, Sanjay Bhanot, Brett P Monia.   

Abstract

Current understanding of microRNA (miRNA) biology is limited, and antisense oligonucleotide (ASO) inhibition of miRNAs is a powerful technique for their functionalization. To uncover the role of the liver-specific miR-122 in the adult liver, we inhibited it in mice with a 2'-O-methoxyethyl phosphorothioate ASO. miR-122 inhibition in normal mice resulted in reduced plasma cholesterol levels, increased hepatic fatty-acid oxidation, and a decrease in hepatic fatty-acid and cholesterol synthesis rates. Activation of the central metabolic sensor AMPK was also increased. miR-122 inhibition in a diet-induced obesity mouse model resulted in decreased plasma cholesterol levels and a significant improvement in liver steatosis, accompanied by reductions in several lipogenic genes. These results implicate miR-122 as a key regulator of cholesterol and fatty-acid metabolism in the adult liver and suggest that miR-122 may be an attractive therapeutic target for metabolic disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16459310     DOI: 10.1016/j.cmet.2006.01.005

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  832 in total

Review 1.  Small RNAs have a big impact on regeneration.

Authors:  Elizabeth J Thatcher; James G Patton
Journal:  RNA Biol       Date:  2010-05-14       Impact factor: 4.652

Review 2.  Post-transcriptional regulation in metabolic diseases.

Authors:  Wook Kim; Eun Kyung Lee
Journal:  RNA Biol       Date:  2012-06-01       Impact factor: 4.652

Review 3.  Developing therapeutic microRNAs for cancer.

Authors:  A G Bader; D Brown; J Stoudemire; P Lammers
Journal:  Gene Ther       Date:  2011-06-02       Impact factor: 5.250

4.  A role for miR-296 in the regulation of lipoapoptosis by targeting PUMA.

Authors:  Sophie C Cazanave; Justin L Mott; Nafisa A Elmi; Steven F Bronk; Howard C Masuoka; Michael R Charlton; Gregory J Gores
Journal:  J Lipid Res       Date:  2011-06-01       Impact factor: 5.922

Review 5.  Epigenetic regulation in alcoholic liver disease.

Authors:  Pranoti Mandrekar
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

6.  miRNAs in human cancer.

Authors:  Xiaomin Zhong; George Coukos; Lin Zhang
Journal:  Methods Mol Biol       Date:  2012

7.  Alterations of Cholesterol Metabolism in Inflammation-Induced Atherogenesis.

Authors:  David P Hajjar; Katherine A Hajjar
Journal:  J Enzymol Metab       Date:  2016-05-31

8.  NEAT1 accelerates the progression of liver fibrosis via regulation of microRNA-122 and Kruppel-like factor 6.

Authors:  Fujun Yu; Zhe Jiang; Bicheng Chen; Peihong Dong; Jianjian Zheng
Journal:  J Mol Med (Berl)       Date:  2017-09-01       Impact factor: 4.599

9.  The effect of miRNA-122 in regulating fat deposition in a cell line model.

Authors:  Yu-Qiang Nie; Jie Cao; Yong-Jian Zhou; Xia Liang; Yan-Lei Du; Yu-Jui Yvonne Wan; Yu-Yuan Li
Journal:  J Cell Biochem       Date:  2014-05       Impact factor: 4.429

Review 10.  MicroRNAs in metabolic disease.

Authors:  Carlos Fernández-Hernando; Cristina M Ramírez; Leigh Goedeke; Yajaira Suárez
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-02       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.